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Summary
Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally 
recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels 
in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as 
hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose 
levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a 
woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a 
viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. 
Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the 
second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the 
patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, 
no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide 
treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some 
cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, 
also during pregnancy.
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Learning points:
•	 Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia.
•	 Hypoglycemia during pregnancy may have serious health implications for mother and fetus.
•	 Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment 
may pose a risk of fetal growth restriction.
•	 In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through 
diet only.
Background
Familial hyperinsulinemic hypoglycemia type 3 (HHF3, 
OMIM #602485) is caused by gain-of-function mutations 
in GCK, the gene encoding glucokinase. In the pancreatic 
beta cell, glucokinase catalyzes the phosphorylation 
of glucose to glucose-6-phosphate, which in turn 
stimulates insulin secretion. Although loss-of-function 
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GCK mutations cause impaired insulin secretion and 
mild hyperglycemia, i.e., maturity onset diabetes of 
young, type 2 (MODY2), activating GCK mutations lead 
to hyperinsulinism and subsequently hypoglycemia (1). 
HHF3 is inherited in an autosomal dominant manner and 
characterized by marked phenotypic variation even within 
families. In accordance, some heterozygous mutation 
carriers may only present postprandial hypoglycemia, 
whereas others experience repeated admissions to hospital 
due to hypoglycemic convulsions and coma (2, 3).
Animal studies have shown that maternal 
hyperinsulinism and hypoglycemia during pregnancy 
increases the risk of fetal malformation and fetal growth 
restriction (4). Further, it has been hypothesized that 
incidences of severe maternal hypoglycemia may have 
damaging impact on the fetal neurological development 
(5). Although somatostatin analogues may lower insulin 
secretion and reduce the risk of hyperinsulinemic 
hypoglycemia, administration of these drugs during 
pregnancy is generally not recommended due to 
inadequate data on potential effects on the fetus. Some 
reports suggest that somatostatin analogues can be used 
without deleterious effects to the fetus, but recently 
reservations have been made upon the possible risk of 
severe fetal growth retardation and likely association to 
neonatal necrotizing enterocolitis (6, 7, 8).
Hyperinsulinemic hypoglycemia in pregnancy 
thus forms a medical dilemma as hypoglycemia as well 
as treatment with somatostatin analogues may cause 
intrauterine growth retardation. To our knowledge, only 
two previous publications have addressed this topic (6, 7).
We present pregnancy outcomes in a woman with 
symptomatic HHF3 treated with octreotide injections in 
one pregnancy and with a low carbohydrate diet only in 
a subsequent pregnancy. During the first pregnancy with 
a viable fetus intrauterine growth retardation (IUGR) 
developed whilst in the second pregnancy with a viable 
fetus, fetal growth velocity was normal.
Case presentation
The patient, a thirty-four-year old Caucasian woman, was 
diagnosed with HHF3 at twenty-three years of age. She was 
obese with BMI of 34 and smoked 20 cigarettes per day 
but was otherwise healthy. The patient had no history of 
severe hypoglycemic episodes, defined as having low blood 
glucose levels that requires assistance from another person 
to treat. Yet, she reported intermittent light-headedness, 
headache and hunger, especially during exercise and when 
trying to lose weight. In 2004, at the time of diagnosis, 
pre-prandial blood glucose ranged 1.9–2.7 mmol/L, and 
during oral glucose tolerance test, the blood glucose level 
was 1.6 mmol/L after 3.5 h with the patient experiencing 
cold sweat and pronounced discomfort. A 72-h fasting 
test was initiated but disrupted after only six hours, as 
blood glucose dropped to 1.9 mmol/L. HbA1c was 4.2% 
corresponding to 22.4 mmol/mol, and levels of plasma 
C-peptide (1014 pmol/L) and plasma insulin (88 pmol/L) 
were increased, whereas plasma pro-insulin was normal 
(11 pmol/L), suggesting hyperinsulinemic hypoglycemia. 
Molecular genetic screening identified a heterozygous 
gain-of-function GCK mutation, c.1367C > T, p.Ala456Val, 
which had previously been reported in a symptomatic 
second-degree relative. The patient was recommended a 
daily calorie intake of 6000–7000 kJ dispersed on 6 meals, 
high in fiber and with a low glycemic index. Diazoxide 
therapy was suggested, but the patient declined, as she was 
unable to accept the possible side effects. Instead, since 
2005, she was treated successfully with intramuscular 
injections of octreotide acetate 10 mg every fourth 
week to prevent severe hypoglycemia. After treatment 
was instituted, the patient reported no hypoglycemic 
symptoms or side effects.
In 2007, she conceived spontaneously but had a 
missed abortion in gestational week 10. There was no 
apparent increase in incidences of hypoglycemia leading 
up to the miscarriage and no conclusions were made upon 
the cause.
The patient became pregnant for a second time 
later the same year, and on her request, octreotide was 
discontinued from gestational age (GA) 11  weeks. Pre-
pregnancy BMI was 39, and she smoked 5 cigarettes per 
day. She was closely followed every fourth week by a 
dedicated obstetric-endocrine team with self-monitoring 
of blood glucose profiles and monitoring of fetal 
growth. At GA 19  weeks, fetal growth was normal and 
no malformations were identified on ultrasound. From 
GA 20 weeks, blood glucose dropped below 3.0 mmol/L 
with increasing frequency and at GA 23 weeks, octreotide 
therapy was reinstituted as the risk of severe hypoglycemia 
with serious health implications for both patient and 
fetus was considered significant. Again, the drug was 
administered as intramuscular injections every fourth 
week. The initial dosage was octreotide acetate 10 mg with 
an increase to 20 mg every fourth week from GA 27 weeks. 
After reinstatement of octreotide acetate injections, the 
pre-prandial blood glucose levels stabilized >3.0 mmol/L. 
Fetal ultrasound measurements showed decreasing growth 
velocity, and at GA 37 weeks, IUGR was diagnosed with 
fetal biometrics 26% below normal (Fig. 1A). The patient 
M Geilswijk and others ID: 16-0126; February 2017
DOI: 10.1530/EDM-16-0126
Octreotide and fetal  
growth restriction
http://www.edmcasereports.com 3
delivered spontaneously in GA 37 + 5 weeks after stripping 
membranes two days earlier. The child had Apgar scores 
10 at 1 min and 10 at 5 min, and birth weight and length 
were 2200 g and 47 cm, respectively. Post-natal molecular 
genetic testing revealed that the child had not inherited 
the familial GCK mutation. The patient decided not to 
breast-feed and octreotide therapy was continued. Data 
regarding the child’s post-natal growth is unfortunately 
not available.
In 2012, the patient conceived for the third time. An 
injection of octreotide had been administrated two weeks 
prior to estimated conception and further administration 
was discontinued due to the possible risk of impaired 
fetal growth. A routine sonographic evaluation for nuchal 
translucency identified a missed abortion corresponding 
to GA 8 + 3 years. Octreotide therapy was not reinstituted, 
and the patient managed blood glucose levels through 
diet only.
In 2013, the patient conceived the fourth time. Her 
weight was 108 kg, corresponding to a BMI of 40, and she 
did no longer smoke. At the first visit in the obstetric clinic 
at GA 8 weeks, she was advised to take small and frequent 
meals 6 times a day, high in fiber and low in simple 
carbohydrates. Again, the patient was followed every fourth 
week to evaluate blood glucose measurements, including 
blood glucose profiles and HbA1c, and fetal growth. Blood 
glucose levels were stable between 3.0 and 5.0 mmol/L 
throughout the first and second trimester (Table  1). In 
GA 29 weeks, pre-prandial blood glucose dropped below 
3 mmol/L, and the diet was adjusted to meals every two 
hours with 10–12 g of complex carbohydrates and a high 
content of fiber and fat. During the third trimester, blood 
glucose levels were predominantly 3.0–4.4 mmol/L with 
only a few measurements of 2.5–2.9 mmol/L and no 
Figure 1
(A) Fetal weight, first pregnancy. Upper and lower red lines marking 97th 
and third percentiles respectively. (B) Fetal weight, second pregnancy. 
Upper and lower red line marking 97th and third percentiles respectively.
Table 1 Blood glucose profiles during the fourth pregnancy, 
first trimester.
Day
Breakfast Lunch Dinner
Pre Post Pre Post Pre Post
3.6 4.5 4.1 4.9 3.6 4.8
3.6 4.6 4.4 4.5 3.2 4.2
3.5 4.4 3.6 3.9 3.0 4.9
3.3 4.6 3.5 4.0 3.4 4.2
3.6 4.4 3.6 4.2 3.5 4.4
3.5 4.3 3.3 4.0 3.2 4.0
3.6 4.6 3.6 4.1 3.3 4.1
3.4 4.5 3.4 3.9 3.3 4.2
3.6 4.4 3.5 4.0 3.5 4.4
3.7 4.5 3.5 4.0 3.3 4.2
4.0 4.6 3.7 4.0 3.4 4.4
3.9 4.2 3.6 4.1 3.5 4.0
3.4 4.0 3.5 4.0 3.6 4.6
4.0 4.6 3.5 4.0 3.3 4.4
4.2 4.8 3.8 4.4 3.4 4.2
3.4 4.0 3.6 4.0 3.5 4.4
3.8 4.2 3.7 4.2 3.6 4.1
3.3 3.9 3.4 4.0 3.1 3.9
3.1 3.8 3.3 3.9 3.0 3.7
3.0 3.7 3.2 4.0 3.5 3.9
 3.1 3.6 3.3 3.9 3.4 3.8
Pre: Pre-prandial blood glucose, mmol/l. Post: Post-prandial blood 
glucose, mmol/l, 1½ hours after meals.
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symptoms of severe hypoglycemia. The fetus showed 
no signs of IUGR, and fetal growth velocity was normal 
throughout the second and third trimester (Fig. 1B). After 
spontaneous labor in GA 39 + 6  weeks, the patient gave 
birth to a healthy child with Apgar scores 10 at 1 min 
and 10 at 10 min, and birth weight and length at 2890 g 
and 48 cm, respectively. Post-natal molecular genetic 
testing showed that the child did not carry the familial 
GCK mutation. Data regarding post-natal growth are 
unfortunately not available.
Discussion
Here, we present pregnancy outcomes in a woman with 
symptomatic HHF3 treated with octreotide injections in 
the first pregnancy and with a low carbohydrate diet only 
in a subsequent pregnancy. Two additional pregnancies 
during octreotide treatment resulted in the 1st trimester 
spontaneous abortions. During the first pregnancy with 
a viable fetus, octreotide injections were instituted from 
GA 23 weeks to maintain blood glucose levels in a normal 
range and prevent severe hypoglycemic events. A decline 
in fetal growth velocity was observed from GA 27 weeks, 
and IUGR was evident at 37  weeks of gestation. In the 
second pregnancy with a viable fetus blood glucose levels 
were managed on a low carbohydrate diet only. The fetal 
growth velocity was normal throughout the pregnancy. 
The patient did not experience incidences of severe 
hypoglycemia in any of the pregnancies and HbA1c levels 
were in the normal range for the second and third trimester 
pregnancy (Figs  2 and 3) (9). No fetal or umbilical cord 
malformations were noticed and neither of the children 
carried the familial gain-of-function GCK mutation. 
Though the patient smoked up to five cigarettes per day 
during the first pregnancy, this is unlikely to explain the 
abrupt decline in fetal growth velocity from the 23rd week 
of gestation. Instead, the intrauterine growth retardation 
observed in the first pregnancy may be ascribed to 
octreotide administration; this factor being the single 
most important difference between the two pregnancies.
Previous reports on the use of octreotide during 
pregnancy are scarce and conflicting. Uneventful 
pregnancies with normal outcomes have been observed 
in acromegalic women and in one case of unspecified 
nesidioblastosis (6, 10). Other investigators report on 
fetal growth retardation and a possible risk of NEC in 
the neonate after intrauterine octreotide exposure (7, 8). 
Animal studies on prenatal development report reduced 
fetal growth and maturation after intrauterine exposure to 
octreotide. Based on these findings, the drug is generally 
not recommended for pregnant women (http://www.
ema.europa.eu/docs/en_GB/document_library/Referrals_
document/Sandostatin_LAR_30/WC500169358.pdf. 
Accessed 27th of March, 2016). Octreotide passes the 
placental barrier and influence the fetus in the same way 
as human somatostatin by decreasing levels of insulin and 
insulin-like growth factor 1 among others (11).
In the present case, the possible damaging effects of 
octreotide may have been further aggravated as familial 
hyperinsulinism in itself may increase the risk of IUGR. 
Skajaa and coworkers proposed that fetal growth in a 
HHF pregnancy could be influenced by the genetic state 
of the fetus, analogously to what is seen in MODY2. Our 
case cannot elucidate this issue, as none of the children 
were carrying the familial GCK mutation and the genetic 
status of the aborted fetuses is unknown. Instead, our case 
indicates that non-carrier fetuses are at risk of growth 
restriction when exposed to octreotide.
In cases of familial hyperinsulinism, octreotide is 
used during pregnancy to prevent severe hypoglycemia 
with the inherent risk of coma and death. Though 
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HbA1c during pregnancies. Normal range (non-pregnant women): 
31–44 mmol/mol. Normal range during the second and third trimester of 
pregnancy: 21–40 mmol/mol (9).
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HbA1c measurements over time. Grey boxes indicating second and fourth 
pregnancy, respectively.
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hypoglycemia has been associated with both congenital 
malformations and impaired fetal growth in animal 
studies, there is no evidence to confirm a similar 
teratogenic effect of hypoglycemia in pregnancy in 
humans (4, 5, 12). In adults, recurrent hypoglycemia is 
associated to a significant decline in cognitive function. 
Similar findings have not been reported in offspring of 
diabetic mothers with recurrent hypoglycemic episodes in 
pregnancy (13). It is speculative whether the more or less 
constant hypoglycemic state seen in HHF3 affects fetal 
cognitive development.
Conclusion
Octreotide administration during pregnancy in 
hyperinsulinism may pose a risk of fetal growth 
retardation. Other dietary interventions with low 
carbohydrate content should be considered before 
octreotide therapy is instituted. Close follow-up of at-risk 
pregnancies is warranted as hypoglycemia in itself may 
lead to fetal growth impairment.
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